Viewing nowCombinationEmpagliflozin/Metformin Extended-Release Tablets 12.5/1000 mg (Empagliflozin, Metformin)
Empagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samhwa Pharmaceutical Co., Ltd.

MFDS item code 202502003 · Approved 2025.07.31 · Insurance code 647805910
Improvement of blood glucose control in adults with type 2 diabetes mellitus
This medication helps improve glycemic control in adult patients with type 2 diabetes in conjunction with dietary and physical exercise. It is particularly suitable for those with insufficient glycemic control and should be used with caution in patients with established cardiovascular disease regarding the occurrence of cardiovascular events. Therefore, this drug is used to enhance glycemic management in type 2 diabetes.
For antidiabetic therapy, the dose of this medicine is determined based on each patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet of the 10/1000 mg or 25/1000 mg extended-release tablet once daily. Patients taking the 5/1000 mg or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medicine is coadministered with a sulfonylurea or insulin, dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used with adjustment of the metformin hydrochloride dose as follows if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45 ml/min or estimated glomerular filtration rate (eGFR) falls below 45 ml/min/1.73m2, this medicine should be discontinued immediately. For patients aged 75 years and older, consider renal function and the risk of volume depletion.
This medication is used for the treatment of type 2 diabetes and contains two active ingredients: empagliflozin and metformin. Before taking this drug, it is crucial to verify that kidney function is normal. It should not be used in patients with significantly reduced kidney function, and regular tests should be conducted to monitor changes in kidney function. This medication can cause a rare but serious side effect known as lactic acidosis. Lactic acidosis is a condition characterized by excessive accumulation of lactic acid in the body, which can lead to symptoms such as malaise, muscle pain, shortness of breath, and abdominal pain. If any of these symptoms occur, you should immediately inform your healthcare provider. Additionally, this drug can increase the risk of hypoglycemia when used in conjunction with insulin or sulfonylureas; therefore, it is important to monitor for hypoglycemic symptoms and adjust insulin doses if necessary. Care should be taken to monitor for infections while taking this medication. Urinary tract infections or genital infections may occur, so any signs of infection should be addressed promptly. If surgery is planned or if undergoing tests involving contrast agents, this medication should be discontinued 48 hours prior to surgery or testing, and can be resumed after confirming normal kidney function. Pregnant women or those with a possibility of pregnancy are advised against using this medication, and breastfeeding should be discontinued while taking this medication. Elderly patients or those at risk of fluid loss, patients with impaired liver or heart function, and those who consume alcohol excessively should use this medication with caution, and regular health check-ups and evaluations are necessary. This medication should be swallowed whole without crushing or chewing, and the coating may be eliminated in the stool, which is a normal occurrence. Lastly, there may be potential interactions with other medications taken simultaneously, so it is important to inform your healthcare provider about any other drugs being used, and it is advisable to avoid alcohol consumption.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to prolong its effectiveness.
Pale pink oval extended-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samhwa Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.